Abzena and UGA Biopharma Announce a Cell Line Expressing a Biosimilar to an Antibody Therapeutic for MS

On October 19, 2017, Abzena plc and UGA Biopharma Gmbh announced that their partnership completed development of an NS0 (murine myeloma) manufacturing cell line.  This cell line expresses a biosimilar of a therapeutic antibody for multiple sclerosis. While the press release does not disclose the originator therapeutic, it notes the originator therapeutic had worldwide sales of approximately $1.9 billion in 2016.